(OA19) Low-Dose-Rate Brachytherapy as Monotherapy for High-Risk Prostate Cancer: 15-Year Outcomes Data

Currently available randomized data suggest favorable outcomes for high-risk prostate cancer (HRPC) patients treated with external beam radiotherapy (EBRT) and brachytherapy in conjunction with hormonal therapy (HT). However, in certain clinical scenarios patients may not be suitable for EBRT, in which case radiation oncologist is tasked with a challenging decision with regards to disease management. In this study we aimed to examine long-term biochemical control and survival with low-dose-rate brachytherapy (LDR-BT) alone for HRPC.

https://ift.tt/2KwEteT